
11/02/2025
A new drug called efruxifermin was found to reverse scarring of the liver in patients with cirrhosis due to non-alcoholic fatty liver disease (now called MASLD).
This new drug is a fusion protein that mimics the effects of fibroblast growth factor 21 (FGF21), which regulates metabolism and protects cells from stress.
Efruxifermin designed by Akero Pharma, has a half-life of about 3 days, allowing it to be administered once a week.
Efruxifermin is undergoing Phase 3 clinical trials in the SYNCHRONY protocol, which includes studies targeting both pre-cirrhotic NAFLD and compensated cirrhosis due to NAFLD. group.